From Bedside To Bench: A New Paradigm For Assessing New Treatments
It is time for payers to stop passively accepting uncertainty and instead help to generate evidence on new medicines, says Hans-Georg Eichler from Austria’s association of insurers.
You may also be interested in...
Industry has warned that reforming the system for evaluating orphan drugs could have serious consequences for patient access.
Industry has have welcomed another delay to the implementation of drug pricing reforms that aim to lower Canadian drugs prices.
A new consortium that has won funding from the French government will focus on developing new treatments, diagnostics and surveillance and make sure that these approaches are properly valued by involving health economists in new drug development.